Table 1.
Study population.
| Variable | |
|---|---|
| Patients, n | 131 |
| Age, median (IQR) | 69.0 (59.0–79.0) |
| Male, n (%) | 79 (60.3) |
| Cerebrovascular risk factors, n (%) | |
| Arterial hypertension | 100 (76.3) |
| Atrial fibrillation | 35 (26.7) |
| Hyperlipidemia | 81 (61.8) |
| Diabetes mellitus | 39 (29.8) |
| Smoking | |
| Non-smoker | 69 (52.7) |
| Previous smoker | 16 (12.2) |
| Current smoker | 31 (23.7) |
| Undetermined | 15 (11.5) |
| Previous stroke or TIA, n (%) | 42 (32.1) |
| Thrombolysis treatment, median (IQR) | |
| Time from symptom onset to treatment (min) | 155 (125.0–180.0) |
| Duration of thrombolysis (min) | 60 (60.0–65.0) |
| rt-PA dose (mg) | 67.0 (58.0–80.8) |
| Medication at enrollment, n (%) | |
| Antihypertensive therapy | 93 (71.0) |
| Angiotensin-converting enzyme inhibitor | 60 (45.8) |
| Alpha blocker | 7 (5.3) |
| Beta blocker | 56 (42.8) |
| Calcium channel blocker | 30 (22.9) |
| Diuretics | 39 (29.8) |
| Antiplatelet druga | 58 (44.3) |
| Anticoagulant drug | 7 (5.3) |
| Lipid lowering therapy | 38 (29.0) |
| Antidiabetic therapyb | 16 (12.2) |
| Laboratory measurements, median (IQR) | |
| INR | 0.98 (0.94–1.03) |
| APTT (s) | 28.5 (26.1–32.1) |
| WBC (G/L) | 7.59 (6.12–9.0) |
| Platelets (G/L) | 207.5 (169.0–254.3) |
| Serum glucose (mmol/L) | 6.5 (5.5–7.9) |
| hsCRP (mg/L) | 3.06 (1.7–5.9) |
| Creatinine (μmol/L) | 78.0 (64.0–97.0) |
IQR, interquartile range; TIA, transient ischemic attack; rt-PA, recombinant tissue plasminogen activator; INR, international normalized ratio; APTT, activated partial thromboplastin time; WBC, white blood cell; hsCRP, high sensitivity CRP.
aAspirin or P2Y12 inhibitor treatment or both.
bInsulin therapy or oral antidiabetic drug therapy.